TY - GEN
AU - Brian Hurley
AU - Allison J. Ober
AU - Vanessa Jacobsohn
AU - Karen Chan Osilla
AU - Keith G. Heinzerling
AU - Erika Litvin Bloom
AU - Katherine Watkins
A1 - 
AB - Psychiatrists, nurse practitioners, and other clinicians who work in mental health settings are in an optimal position to treat co-occurring opioid use and mental health disorders (COD-opioid). The U.S. Food and Drug Administration has approved buprenorphine, naltrexone, and methadone as treatments for opioid use disorder. Of these drugs, buprenorphine/naloxone, buprenorphine, and naltrexone extended-release injectable suspension are available outside federally certified opioid treatment programs and are appropriate for use in mental health settings to treat mental health clients with COD-opioid and enhance the effectiveness of mental health treatment. This guide prepares mental health practitioners to (1) identify clients with co-occurring opioid use and mental health disorders in mental health settings and (2) treat these clients with an appropriate opioid use disorder medication. It provides a practical strategy for treating clients in mental health settings with buprenorphine/naloxone or naltrexone extended-release injectable suspension.;
C4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Education & Workforce; Opioids & Substance Use
DO - 10.7249/TLA928-2
LA - English
M1 - Generic
N2 - Psychiatrists, nurse practitioners, and other clinicians who work in mental health settings are in an optimal position to treat co-occurring opioid use and mental health disorders (COD-opioid). The U.S. Food and Drug Administration has approved buprenorphine, naltrexone, and methadone as treatments for opioid use disorder. Of these drugs, buprenorphine/naloxone, buprenorphine, and naltrexone extended-release injectable suspension are available outside federally certified opioid treatment programs and are appropriate for use in mental health settings to treat mental health clients with COD-opioid and enhance the effectiveness of mental health treatment. This guide prepares mental health practitioners to (1) identify clients with co-occurring opioid use and mental health disorders in mental health settings and (2) treat these clients with an appropriate opioid use disorder medication. It provides a practical strategy for treating clients in mental health settings with buprenorphine/naloxone or naltrexone extended-release injectable suspension.;
PY - 2021
RN - https://doi.org/10.7249/TLA928-2
SN - 10.7249/TLA928-2
T1 - Medication management of co-occurring opioid use disorder in mental health settings: A guide for practitioners
TI - Medication management of co-occurring opioid use disorder in mental health settings: A guide for practitioners
U1 - Grey Literature; Education & Workforce; Opioids & Substance Use
U3 - 10.7249/TLA928-2
U4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - https://doi.org/10.7249/TLA928-2
VO - 10.7249/TLA928-2
Y1 - 2021
ER -